… The AURA3 trial showed that in T790M mutation-positive advanced lung cancer, osimertinib
… for T790M mutations, which were detected in 52.2% (47/90 patients). T790M mutation was …

… clinical data and T790M mutation in rebiopsy after EGFR tyrosine kinase inhibitors (EGFR-TKIs)
failure, and explored the prognosis of T790M-… Our results are beneficial in the choice of …

Background This study aims to determine the predictors of acquired exon 20 T790M
mutation in advanced non-small cell lung cancer (NSCLC) patients harbouring sensitizing …

… is the development of T790M mutation in exon 20 of the … their T790M mutation is under
LOD, and can still benefit from third-generation TKI treatment. In survival analysis, TP53 mutation …

… The hypothesis that the allelic context of C797X/T790M has implications for treatment is on
the … profiles and assessed associations between clinical outcomes and C797X status. Results …

… to categorize different immune phenotypes of EGFR-mutated ADC, leading to distinct clinical
outcomes and varied potentials to develop T790M mutations. To our knowledge, this is not …

… indication for baseline T790M mutation in EGFR mutated NSCLC. The availability of third
generation TKI osimertinib as first-line treatment on the basis of the results of FLAURA trial is …

… patient population. Here, we report the survival outcome of patients with EGFR-mutated NSCLC
… cytologically proven LM according to osimertinib treatment and T790M mutational status. …

… Osimertinib therapy yielded favorable efficacy and safety outcomes in patients with EGFR
T790M mutation-positive NSCLC who had a poor PS. Specifically, the ORR was 53% and the …

… T790M mutations did not have significantly worse outcomes than those with positive … with
T790M mutation than for NSCLC without T790M mutation. Detection of the T790M mutation …